Health Canada Approves New 15-Day Continuous Glucose Monitoring System
Health Canada has officially authorized the use of the Dexcom G7, a new continuous glucose monitoring (CGM) system. This device is designed to help adults aged 18 and older manage their blood sugar levels more effectively.
Unlike older versions of the technology, the G7 system is approved for use over a 15-day period. This longer duration between sensor changes is expected to provide more convenience for patients who need to track their glucose levels daily.
Continuous glucose monitors are small, wearable devices that provide real-time data to users. By tracking blood sugar levels throughout the day and night, these systems help people living with diabetes make informed decisions about their diet, exercise, and medication.
This authorization marks an important step for diabetes care in Canada. By allowing patients to wear the sensor for a longer time, the new system aims to reduce the number of times users must replace their equipment, making the management of the condition simpler and more consistent.
Health Canada continues to evaluate new medical technologies to ensure they meet safety and performance standards. Patients interested in the Dexcom G7 are encouraged to speak with their healthcare providers to determine if this new system is the right choice for their specific health needs.